 |
|
|
||||||||||||||
 |
|
|
Tell your patients they are at risk for diabetes before their bodies do
The PreDx™ Diabetes Risk Test is a quantitative test* that employs a complex algorithm to analyze a defined set of biomarkers implicated in the development of diabetes. The test is simple to obtain, performed on a fasting blood sample and simple to interpret — providing a single score that summarizes a patient's personalized risk for developing Type 2 diabetes within 5 years.
This fasting blood test provides you and your patient with a PreDx™ Diabetes Risk Score — a personalized diabetes prediction score with a number between 1 (least risk) and 10 (highest risk). This test is offered as a service exclusively by the Tethys Clinical Laboratory. The information provided by the PreDx Diabetes Risk Test may be used by the physician in conjunction with other clinical indicators to develop an effective diabetes prevention program.
Now instead of diagnosing diabetes, you can help prevent it.
*Performed exclusively by the Tethys Clinical Laboratory
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)